Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

• Published in: Mediators of inflammation 2021-10, Vol.2021, p.3125922-9
• Main Authors: Wielińska, Joanna, Świerkot, Jerzy, Kolossa, Katarzyna, Bugaj, Bartosz, Chaszczewska-Markowska, Monika, Jeka, Sławomir, Bogunia-Kubik, Katarzyna
• Format: Article
• Language: English
• Subjects: Adalimumab; Alleles; Ankylosing spondylitis; Arthritis; Binding sites; Biomarkers; Body mass index; Chromosomes; Disease; Disease susceptibility; Ethylenediaminetetraacetic acid; Gene polymorphism; Genes; Genetic aspects; Genetic polymorphisms; Genetic Predisposition to Disease - genetics; Genotyping; Humans; Inflammatory diseases; Interleukin-17 - genetics; Joint diseases; Nonsteroidal anti-inflammatory drugs; Patients; Polymorphism, Genetic; Polymorphism, Single Nucleotide - genetics; Receptors, Interleukin-7 - genetics; Rheumatic diseases; Rheumatoid arthritis; Rheumatology; Spondylitis, Ankylosing - genetics; Statistical analysis; Tumor necrosis factor; Tumor Necrosis Factor Inhibitors; Tumor necrosis factor-TNF
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2021/3125922

IL-17A and IL-17F together with their coreceptor (IL-17RA/RC) were reported to play a significant role in the pathogenesis of spondyloarthritis. The group of axial spondyloarthritis comprises ankylosing spondylitis (AS), a rheumatic disease characterized by chronic inflammation of the joints in the spine. This study is aimed at investigating IL-17A, IL-17F, IL-17RA, and IL-17RC polymorphisms as potential biomarkers of disease susceptibility, clinical parameters, and anti-TNF treatment outcome in a cohort of Polish ankylosing spondylitis patients. In total, 328 subjects, including 138 AS patients and 190 healthy volunteers, participated in the study. Genotyping of IL-17A rs2275913 (G/A), IL-17F rs763780 (A/G), IL-17RA rs4819554 (A/G), and IL-17RC rs708567 (G/A) was performed on real-time PCR instrument using LightSNiP assays. No significant differences were revealed in genotype and allele distribution between patients and controls despite the association of the IL-17RC rs708567 AA homozygosity with the earlier onset of the disease. Moreover, some relationships between IL-17F rs763780 and IL-17RA rs4819554 polymorphisms with clinical parameters related to the disease activity and anti-TNF treatment outcome were observed. IL-17F rs763780 G allele was found to be associated with high disease activity and BASDAI after 6 months and poor response to the treatment while higher VAS values were more common among IL-17RA rs4819554 G variant carriers. In conclusion, the IL-17F rs763780 polymorphism should be considered as a promising biomarker of disease activity and anti-TNF treatment outcome. The IL-17RA rs48419554 G allele may serve as a potential marker of disease severity in Polish AS patients.